Melanoma Clinical Trials in Cleveland

Showing 241-260 of 275 trials

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550

MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with colon cancer, breast cancer, and melanoma. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies will be taken of a tumor before and once during treatment to measure the effects of the drug. Blood samples will be taken to measure the amount of drug in the blood.

MelanomaColonic NeoplasmsBreast Neoplasms

Pfizer79 participantsStarted Feb 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +14 more locations

COMPLETEDPhase 2< 1 mile

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

NCT00026520

RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with thalidomide in treating patients who have stage IV melanoma.

Melanoma (Skin)

SWOG Cancer Research NetworkStarted Nov 2001

Mobile, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +91 more locations

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Melanoma Trials in Other Cities

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Cleveland